Project B07
GvHD therapy with in vitro expanded donor regulatory T cells.
Site: Regensburg
Principal Investigators: PD Dr. rer. nat. Petra Hoffmann, Prof. Dr. rer. nat. Michael Rehli, Prof. Dr. med. Matthias Edinger
Summary Project B07
We previously showed that donor CD4+CD25+Foxp3+ regulatory T cells (Treg) prevent lethal acute GvHD after MHC-mismatched BMT in murine models. We now observed that they also ameliorate ongoing GvHD and the prerequisites for efficacious GvHD therapy are studied in this project. For this purpose, the migration pattern of in vitro expanded donor Treg is examined, their organ-specific T cell receptor (TCR) repertoire selection and their site-specific functional status. Finally, we investigate whether their therapeutic efficacy in GvHD can be enhanced by the overexpression of alloreactive TCRs or tissue-specific homing receptors.
Selected Publications
Delacher, M. et al. (2024) ‘The effector program of human CD8 T cells supports tissue remodeling’, Journal of Experimental Medicine, 221(2), p. e20230488. Available at: https://doi.org/10.1084/jem.20230488. Data available in GSE223989
Dittmar, D.J. et al. (2024) ‘Donor regulatory T cells rapidly adapt to recipient tissues to control murine acute graft-versus-host disease’, Nature Communications, 15(1), p. 3224. Available at: https://doi.org/10.1038/s41467-024-47575-z. Data available in GSE223800
Contact to Principal Investigators
PD Dr. rer. nat. Petra Hoffmann
LIT – Leibniz Institute for Immunotherapy (former RCI)
c/o Universitätsklinikum Regensburg
Franz-Josef-Strauß-Allee 11
93053 Regensburg
T: +49 941 944-38492
petra.hoffmann(at)ukr.de
Prof. Dr. rer. nat. Michael Rehli
University Hospital Regensburg
Department of Internal Medicine III
Franz-Josef-Strauß-Allee 11
93053 Regensburg
T: +49 941 944-38487
michael.rehli(at)ukr.de
Prof. Dr. med. Matthias Edinger
University Hospital Regensburg
Department of Internal Medicine III
Franz-Josef-Strauß-Allee 11
93053 Regensburg
T: +49 941 944-5582
matthias.edinger(at)ukr.de
